Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
2.28
Oct 30 • 3:59 PM ET Dollar change-0.16 Percentage change(-6.56%)
Aftermarket Close
2.28
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
459.48M
Enterprise Value
480.71M
Income
-6.78M
Sales
221.55M
Book/sh
0.35
Cash/sh
0.28
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
275
IPO
Jan 31, 1997
P/E
-
Forward P/E
-
PEG
-
P/S
2.07
P/B
6.56
P/C
8.17
P/FCF
-
EV/EBITDA
-
EV/Sales
2.17
Quick Ratio
1.07
Current Ratio
1.83
Debt/Eq
1.10
LT Debt/Eq
0.62
Option/Short
Yes / Yes
EPS (ttm)
-0.03
EPS next Y
-0.01
EPS next Q
-0.01
EPS this Y
43.75%
EPS next Y
72.22%
EPS next 5Y
-
EPS past 3/5Y
30.31% 25.82%
Sales past 3/5Y
8.35% 17.53%
EPS Y/Y TTM
65.57%
Sales Y/Y TTM
15.09%
EPS Q/Q
50.67%
Sales Q/Q
9.53%
Insider Own
5.38%
Insider Trans
-2.72%
Inst Own
75.82%
Inst Trans
0.65%
ROA
-3.24%
ROE
-10.81%
ROIC
-5.98%
Gross Margin
51.84%
Oper. Margin
-12.67%
Profit Margin
-3.06%
SMA20
-1.34%
SMA50
-7.62%
SMA200
-6.91%
Trades
Shs Outstand
201.46M
Shs Float
190.68M
52W High
3.47 -34.29%
52W Low
1.38 65.22%
Volatility
4.25% 4.00%
ATR (14)
0.10
RSI (14)
43.04
Beta
1.84
Rel Volume
0.71
Avg Volume
2.12M
Volume
1,503,459
Perf Week
-2.15%
Perf Month
-1.72%
Perf Quarter
6.05%
Perf Half Y
-16.18%
Perf YTD
10.68%
Perf Year
62.86%
Perf 3Y
74.05%
Perf 5Y
-65.45%
Perf 10Y
-53.56%
Prev Close
2.44
Price
2.28
Change %
-6.56%
Consensus
Strong Buy
Avg. Price Target
$5.12
Implied Upside
+124.6%
Analysts8incl. previous ratings
Rating Distribution6 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 01, 2026Upgrade
BBTIG Research
Neutral → Buy$4+75.4%
Apr 12, 2024Initiated
CCraig Hallum
Buy$5+119.3%
Jan 20, 2023Downgrade
BBTIG Research
Buy → Neutral
Jan 17, 2023Downgrade
SStephens
Overweight → Equal-Weight$3.75+64.5%
Oct 08, 2020Resumed
BBTIG Research
Buy$9+294.7%
Jun 16, 2020Resumed
CCantor Fitzgerald
Overweight$9+294.7%
Feb 26, 2020Initiated
BBTIG Research
Buy$7+207.0%
Nov 13, 2019Upgrade
BBTIG Research
Neutral → Buy$7+207.0%
Aug 28, 2019Initiated
SF logoSStifel
Buy
Aug 23, 2019Resumed
SStephens
Overweight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jensen ChrystalChief Legal OfficerAug 17 '26Sale2.9830,00089,529936,657Aug 17 08:18 PM
CHRYSTAL NIKOLE JENSENOfficerAug 17 '26Proposed Sale2.9830,00089,529Aug 17 04:39 PM
Jayaraman Vivek KChief Executive OfficerJul 16 '26Sale3.1616,66652,6652,232,211Jul 20 05:03 PM
VIVEK K JAYARAMANOfficerJul 16 '26Proposed Sale3.1616,66652,665Jul 16 04:15 PM
Green Kevin DennisChief Financial OfficerJun 30 '26Sale2.9433,67699,1051,062,188Jul 02 07:19 PM
Jayaraman Vivek KChief Operating OfficerJun 30 '26Sale2.9442,359124,6581,694,348Jul 02 07:18 PM
Jensen ChrystalChief Legal OfficerJun 30 '26Sale2.9424,32971,598966,657Jul 02 07:15 PM
Greenman William MarinerPresident and CEOJun 30 '26Sale2.94101,919299,9375,053,036Jul 02 07:13 PM
BJERKHOLT ERICDirectorJun 09 '26Sale2.6020,45453,180261,679Jun 11 09:17 PM
ERIC BJERKHOLTDirectorJun 09 '26Proposed Sale2.6020,45453,180Jun 09 04:12 PM
Jayaraman Vivek KChief Operating OfficerMay 29 '26Sale3.0016,66750,0011,656,707Jun 02 07:46 PM
VIVEK K JAYARAMANOfficerMay 29 '26Proposed Sale3.0016,66750,001May 29 04:13 PM
Jayaraman Vivek KChief Operating OfficerMay 01 '26Sale3.0016,66750,0011,673,374May 05 06:31 PM
RICHARD J BENJAMINOfficerMay 01 '26Proposed Sale2.8276,209214,627May 01 04:08 PM
VIVEK K JAYARAMANOfficerMay 01 '26Proposed Sale3.0016,66750,001May 01 04:07 PM
Jayaraman Vivek KChief Operating OfficerMar 12 '26Sale1.66165,200273,7691,747,674Mar 16 07:44 PM
Greenman William MarinerPresident and CEOMar 12 '26Sale1.66447,757742,0234,998,493Mar 16 07:44 PM
Green Kevin DennisChief Financial OfficerMar 12 '26Sale1.66127,544211,3661,040,551Mar 16 07:44 PM
Benjamin Richard JChief Medical OfficerMar 12 '26Sale1.66101,740168,604777,361Mar 16 07:43 PM
Green Kevin DennisChief Financial OfficerMar 05 '26Sale2.0655,225113,9021,195,891Mar 09 09:56 PM
Green Kevin DennisChief Financial OfficerMar 06 '26Sale2.0127,79655,7451,168,095Mar 09 09:56 PM
Benjamin Richard JChief Medical OfficerMar 05 '26Sale2.0661,233126,305943,762Mar 09 09:35 PM
Benjamin Richard JChief Medical OfficerMar 09 '26Sale1.8840,42676,029879,101Mar 09 09:35 PM
Benjamin Richard JChief Medical OfficerMar 06 '26Sale2.0124,23548,603919,527Mar 09 09:35 PM
Jensen ChrystalChief Legal OfficerMar 06 '26Sale2.0130,84561,8601,059,139Mar 09 09:31 PM
Jayaraman Vivek KChief Operating OfficerMar 06 '26Sale2.0134,09468,3761,912,874Mar 09 09:30 PM
Greenman William MarinerPresident and CEOMar 06 '26Sale2.0178,187156,8045,446,250Mar 09 09:28 PM
RICHARD J BENJAMINOfficerMar 09 '26Proposed Sale1.8840,42676,029Mar 09 04:09 PM
KEVIN D GREENOfficerMar 05 '26Proposed Sale2.0655,225113,902Mar 05 05:03 PM
RICHARD J BENJAMINOfficerMar 05 '26Proposed Sale2.0661,233126,299Mar 05 05:00 PM
Jensen ChrystalChief Legal OfficerNov 24 '25Sale1.7055,00093,500728,294Nov 26 04:07 PM
CHRYSTAL NIKOLE JENSENOfficerNov 24 '25Proposed Sale1.7055,00093,500Nov 24 05:17 PM
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
Executive Chairman of the BoardMr. William M. Greenman
CEOMr. Vivek K. Jayaraman
VP of Finance & CFOMr. Kevin D. Green CPA
Chief Legal OfficerMs. Chrystal N. Jensen J.D.
Ph.D.Dr. Richard J. Benjamin MBChB